



Review Article

Immunotherapy a New Hope for Cancer Treatment: A Review

¹Fatemeh Nouri Rouzbahani, ¹Mohammad Shirkhoda, ¹Feridon Memari, ^{1,2}Hassan Dana, ¹Ghanbar Mahmoodi Chalbatani, ¹Habibollah Mahmoodzadeh, ³Nasim Samarghandi, ¹Elahe Gharagozlou, ⁴Mohammad Hosein Mohammadi Hadloo, ¹Ali Reza Maleki, ¹Ehsan Sadeghian, ²Elham Zainali Nia, ⁵Nedazainali Nia, ¹Farimah Hadjiloei, ⁶Omid Rezaeian, ⁶Saeed Meghdadi, ¹SeyedRohollah Miri, ⁷Fatameh Jafari, ⁸Elham Rayzan and ²Vahid Marmari

¹Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran

²Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran

³Department of Immunology, School of Medicine, University of Medical Sciences, Isfahan, Iran

⁴Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

⁵Department of Biology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran

⁶Department of Biology, Nour Danesh Institute of Higher Education, Isfahan, Iran

⁷Paramedical Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁸International Hematology/Oncology of Pediatrics Experts, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Iran

First, Second and Third author contributed equally to this work

Abstract

Cancer is a major burden of disease worldwide with considerable impact on society. The tide of immunotherapy has finally changed after decades of disappointing results and has become a clinically validated treatment for many cancers. Immunotherapy takes many forms in cancer treatment, including the adoptive transfer of ex vivo activated T cells, oncolytic viruses, natural killer cells, cancer vaccines and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. Recently, cancer immunotherapy has received a high degree of attention, which mainly contains the treatments for programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), chimeric antigen receptors (CARs) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Here, this paper reviewed the current understandings of the main strategies in cancer immunotherapy (adoptive cellular immunotherapy, immune checkpoint blockade, oncolytic viruses and cancer vaccines) and discuss the progress in the synergistic design of immune-targeting combination therapies.

Key words: Immunotherapy, CAR-T cell therapy, CTLA4, Combination therapies and programmed death ligand 1 (PD-L1)

Citation: Fatemeh Nouri Rouzbahani, Mohammad Shirkhoda, Feridon Memari, Hassan Dana, Ghanbar Mahmoodi Chalbatani, Habibollah Mahmoodzadeh, Nasim Samarghandi, Elahe Gharagozlou, Mohammad Hosein Mohammadi Hadloo, Ali Reza Maleki, Ehsan Sadeghian, Elham Zainali Nia, Nedazainali Nia, Farimah Hadjiloei, Omid Rezaeian, Saeed Meghdadi, SeyedRohollah Miri, Fatameh Jafari, Elham Rayzan and Vahid Marmari, 2018. Immunotherapy a new hope for cancer treatment: A review. Pak. J. Biol. Sci., 21: 135-150.

Corresponding Author: Ghanbar Mahmoodi Chalbatani, Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran
SeyedRohollah Miri, Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran

Copyright: © 2018 Fatemeh Nouri Rouzbahani *et al.* This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Competing Interest: The authors have declared that no competing interest exists.

Data Availability: All relevant data are within the paper and its supporting information files.

INTRODUCTION

Today, cancer is one of the most widespread diseases with high mortality rates worldwide and as one of the serious problems and challenges of health and treatment¹. According to global cancer statistics, cancer is the second leading cause of death worldwide. In the 21st century, Cancer has become the number one cause of deaths in developed countries^{2,3}. For example, colorectal cancer with more than 1.2 million new cases resulted in 600 thousand deaths annually and ranks fourth in terms of mortality worldwide⁴. Only in the United States, annually about 50,000 people will die of the disease and nearly 135,000 new cases will be diagnosed⁵. 90-95% of cancer cases are a consequence of environmental factors result in gene mutations and the remainder 5-10% are due to inherited genetic alterations⁶. Each year, tens of millions of people are diagnosed with cancer around the world and more than half, eventually, die⁷. Among multi-model cancer treatment strategies, including surgery, hormonal therapy, radiotherapy and chemotherapy, immunotherapy has revolutionized the treatment of cancer. Immuno oncology is an exciting field of cancer treatment with the potential for impacting the management of numerous malignancies⁸ which has recently received a considerable rise⁹. The major goal of cancer immunotherapy is to alleviate tumor-associated suppression of anti-cancer immune responses¹⁰. The idea of using patient's immune system against cancer-cells dates back to 1997, since the immune system response versus virulent cells during initial transformation in the immune surveillance process was discovered^{11,12}. Cancer immunotherapy, which sometimes called immune-oncology, induces the patient's own immune system¹³ and attempts to harness the exquisite power and specificity of the immune system for cancer treatment¹⁴. Immunotherapies against cancers consist of diverse approaches, ranging from stimulating effector mechanisms to counteracting inhibitory and suppressive mechanisms⁹. By the rapid increase in scientists' knowledge about the immune system, small molecules, peptides, recombinant antibodies, vaccines as well as cellular therapeutic modalities are being applied to manipulate the immune response to treat cancer. Currently, immunotherapies have provided remarkable benefits against cancer¹⁵. The recent clinical successes in cancer immunotherapies, such as immune checkpoint blockade, have reaffirmed the importance of the host immune system in preventing and eliminating malignancies¹⁶. Since cancer is still one of the challenges facing human being in the field of treatment and because

single-drug therapies are not effective in the treatment of cancers, combining two or more therapies with different mechanisms will bring more success. In cancer treatment, so this article will provide a general overview of current immunotherapy in cancer management and also a series of promising heuristic treatments for cancer that can provide real and more useful research patterns.

Cancer vaccines: Cancer vaccines have been designed since three decades ago^{17,18}. The goal of cancer vaccines is to activate and expand cancer-specific T cells, which removes cancerous cells by recognizing their neo-antigens¹⁹. These neo-antigens are created by cancer-specific DNA alterations result in a unique peptide sequence^{20,21}. The vaccines are created based on targeting tumor-associated antigens that are preferentially expressed in cancer cells, which are the microscopic markers distinguishing cancer cells from the normal ones²². Cancer cells can contain hundreds of neo-antigens which are specific to each patient's tumor for instance growth associated factors or unique antigens to malignant cells owing to somatic mutation²³. Cancer vaccines are highly specific and are expected to affect only a single individual because they are designated based on the unique cancer antigens and are able to stimulate the immune system in order to reinforce the immunity to response against cancerous cells^{24,25}. Scientists have developed two types of cancer vaccines, therapeutic and preventive. Several analyses have been carried out on therapeutic cancer vaccines over past two decades in order to replicate successes and failures, on the way of clarifying future directions for more vaccine efforts²⁶. Most cancer vaccines are therapeutic²⁷ designed to treat an established disease, such as cancer, mainly by evoking cellular (T-cell-based) immune responses²⁸. Therapeutic cancer vaccines are used to omit cancerous cells through strengthening patient's immune response, particularly CD8+ T cell-mediated responses, with the assistance of suitable adjuvants^{29,30}. Therapeutic cancer vaccines are used to enhance neo antigen's recognition and to decrease the immune tolerance³¹. Preventive vaccines are used for disease prevention and have been developed against the oncogenic viruses. Oncogenic viral antigens have been identified in virus-induced cancers such as human papillomavirus (HPV)-associated cervical cancer, hepatitis B virus-associated hepatocellular carcinoma and human herpesvirus 8-associated Kaposi sarcoma³². The HPV and HBV vaccines have significantly decreased the risk of related cancers³³. Multiple clinical trials³⁴ have proved that after testing HPV vaccines for the prevention




Fig. 1: Schematic picture of the key steps in preparation of cancer vaccines⁴⁴

of cervical and HPV positive oral cancers, HPV prevalence among females aged 14-19 had decreased by 64% and had decreased by 34% in females who were 20-24 years old³⁵. Currently approved vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), provide effective protection against chronic HPV infection type 16 and 18 and also prevent cervical intraepithelial neoplasia, adenocarcinoma in situ and cervical cancer³⁶. In order to produce cancer vaccines, in some cases, tumor-associated lymphocytes are being isolated and after *in vitro* amplification are being reinjected to patient's body. The same can be done with idiotypic antibodies that are produced by the patient and specifically directed against tumor cells²⁰. Several kinds of cancer vaccines exist, such as dendritic cell-based (DC) vaccines^{37,38}, peptide vaccines^{39,40}, genetic vaccines⁴¹ and cancer cell vaccines⁴². As DCs are central players in initiating the antigen-specific immune response, it seemed logical to utilize them for cancer immunotherapy⁴³ (Fig. 1).

During DC vaccine immunotherapy, stem cells are isolated from peripheral blood and will develop into DCs in an *in vitro* cell culture. DCs then are loaded with cancer patients become sensitized. These sensitized DCs are infused intradermal and travel to the lymph nodes. The DCs instruct specific lymphocyte to multiply. Multiple clinical trials have now been conducted using DC vaccines targeting various cancer types, such as metastatic prostate cancer, metastatic lung cancer, renal cell carcinoma, brain cancers, melanoma, acute myeloid leukemia, pancreatic cancer and others⁴⁵⁻⁴⁸. Although all cancer vaccines are beneficial, the most important long-term concern is the induction of autoimmunity⁴⁹ that depends on the tumor antigen which is targeted and the elicited response. It seems

that the coming years will clarify the emergence of cancer vaccines as a major modality for cancer treatment⁵⁰.

Oncolytic virus therapy: Oncolytic virus therapy (OVT) as a new development in cancer therapy, has emerged over past few decades^{51,52}. The role of viruses in the cancer treatment was discovered about one century ago⁵³. Over the course of the 20th century, further anecdotal evidence emerged that viral infections could induce remission in various cancer types^{54,55}. Virotherapy is based on the administration of oncolytic viruses⁵⁶⁻⁶⁰. Oncolytic virotherapy is a subtype of gene therapy that uses actively replicating viruses⁶¹. The basis of OV therapy is that certain viruses can selectively infect and lyse cancer cells by exploiting altered signaling pathways in the tumor cells⁶² while leaving healthy cells unaffected⁶³⁻⁶⁷. Oncolytic viruses replicate in cancerous cells and cause tumor cell death⁵⁶. Such oncolysis is mostly an immunogenic type of cancer cell death (ICD)⁶⁸. These viruses destroy tumors through two major mechanisms: selective replication within neoplastic cells, resulting in a direct lytic effect on tumor cells and induction of systemic antitumor immunity⁶⁹. Inside a cancer cell, the virus replicates and secretes GM-CSF until the cell lysis release more viruses, GM-CSF and antigens⁷⁰. The expression of GM-CSF stimulates the manufacture of granulocytes and monocytes that can stimulate adaptive immunity against tumor-associated antigens⁷¹. The T cells are now programmed to identify cancer cells throughout the body. This approach has a promise of eliminating not only the infective tumor but also secondary tumors that may result from metastatic growth (Fig. 2).

The key advantageous characteristics of any OV are specificity, potency and safety, specificity for targeted cancer,




Fig. 2: Mechanism of oncolytic virus therapy⁷²

potency to kill infected cells and safety to avoid adverse reactions and pathogenic reversions⁷³. Oncolysis can be a natural feature of the virus, such as reovirus or genetically engineered OV, like adenovirus and renders oncolytic virotherapy⁷⁴. Until now, more than twenty viruses with oncolytic activity have been characterized⁷⁵ such as Polio virus which is used for treating glioblastoma that is a very aggressive cancer^{76,77}. Picornavirus Seneca Valley virus (Picornavirus and Seneca Valley virus), which can infect neuroendocrine tumors such as small cell lung cancer^{73,78,79}. OVs, like reovirus⁷⁴, HSV^{80,81} or vaccinia virus⁸², can induce tumor-specific adaptive immune responses and indirectly cause cancer cell death. The combination of oncolytic viruses with current cancer immunotherapies (such as anti PD1 and anti PDL1 blockades) has the potential to potentiate antitumor effects⁸³. An oncolytic adenovirus expressing a mini-antibody that blocks PDL1 improved the antitumor effects of CAR-T cells in a human prostate cancer xenograft model⁸⁴. Oncorine is a modified adenovirus vector that can treat carcinoma in combination with chemotherapy⁸⁵. First HSV based oncolytic virus, talimogene laherparepvec (T-VEC) (IMLYGIC), was approved in 2015 by the FDA which is the modified form of herpes simplex virus, is used for patients with locally advanced or nonresectable melanoma⁸⁶⁻⁹⁰. A study has already shown the improved efficacy of T-VEC in combination with CTLA-4 inhibitor ipilimumab⁹¹. The viral gene encoding ICP47 which blocks antigen presentation by infected cells is deleted in T-VEC and this leads to immune response enhancement⁹². ICP47 blocks the function of the TAP (transporter associated with antigen processing) and thus prevents infected cells from presenting antigen to CD8+ T cells⁹³. Ipilimumab enhances T cell priming by inhibiting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), a receptor involved in the negative feedback loop that blocks a costimulatory signal from DCs⁹⁴. Development of oncolytic viruses as promising therapeutic

agents, requires careful attention to establish appropriate clinical trial, dosing regimens, pharmacodynamic assays, educational programs addressing biosafety concerns as well as new manufacturing and regulatory pathways⁶⁹. Choosing virus classes to target specific tumor types, should soon become standard practice⁹⁵.

Adoptive T cell therapy: The adoptive transfer of T cells was a pivotal experimental technique used more than half a century ago to establish that cellular components of the immune system could reject tumors⁹⁶⁻⁹⁸. The goal of adoptive T cell therapy (ACT) is to generate a robust immune-mediated antitumor response through the *ex vivo* manipulation of T cells⁹⁹. The ACT is genetically engineering a patient's T cells to express chimeric antigen receptors (CARs) which recognize and attack cancerous cells¹⁰⁰. ACT refers to the extraction, *ex vivo* expansion and subsequent return of an individual's native immune cells for the express purpose of treating disease. In the context of cancer immunotherapy, the patient's own T cells are genetically modified so that they can specifically target and kill cancer cells via recognition of specific antigens expressed on the cancer cell surface¹⁰¹. Genetic modification of T cells is a quick and reliable process and clinical trials of genetically modified T cells targeting a variety of malignancies have been carried out¹⁰²⁻¹⁰⁶. After the patient's native T cells are harvested and then reprogrammed via genetic modification, they are subsequently reintroduced back to the patient¹⁰⁷. The two most commonly toxicities with CAR T cell therapies are cytokine release syndrome (CRS), that caused hypotension, high fever, hypoxia, and/or multi-organ toxicity and a CAR T cell-related encephalopathy syndrome (CRES), typically distinguished by a toxic encephalopathic state with symptoms of confusion, delirium, occasionally seizures and cerebral edema¹⁰⁸⁻¹¹¹. To date, CAR T cell therapies have been most efficacious in patients with B cell ALL¹¹². The

Table 1: Factors responsible for limited success of CAR T cell therapy against solid tumors

Drawbacks	Reference
Reasons of limited success of CAR T cell therapy	
Lack of a unique tumor-associated antigen (TAA) in most cancers	Brentjens <i>et al.</i> ¹⁰⁰
Inability of <i>ex vivo</i> expanded CAR T cells to persist and proliferate following adoptive transfer	
Lack of survival and growth factors (e.g., IL-2)	
Presence of immunosuppressive molecules and cells	
Metabolically hostile tumor micro environment	

excitement of cell-based therapy was followed by the use of engineered chimeric antigen receptor (CAR) T cells directed at TAAs expressed on the tumor cell surface, typically CD19 in B cell malignancies¹¹². Initial clinical trials using CAR T cells have all focused on targeting CD19-based on its cell surface expression in most leukemia, lymphomas and its function^{113,114} which is an ideal antigen because it is ubiquitously expressed on a broad range of differentiated B cells but it is not expressed on hematopoietic stem cells or any other essential cell types¹¹⁵⁻¹¹⁷ limiting potential' on target-off tumor' toxicity. Indeed, in 2017, the FDA approved the Tisagenlecleucel, that is CD19 CAR T cell product, for the treatment of pediatric and young adult patients with relapsed and/or refractory B cell precursor acute lymphoblastic leukemia and axicabtageneclisoleucel (Yescarta, Kite Pharma, Inc.) to treat adults with certain types of B cell lymphoma¹⁰⁰. Indeed, CAR T cells are susceptible to PD-1-mediated inhibition and, therefore, the combination of CAR T-cell therapy with monoclonal antibody immune-checkpoint inhibitors is an obvious progression to protect CAR-T-cell function within the tumor microenvironment¹¹⁸. The demonstration of clinical efficacy in trials using CAR T cell therapy are, at present, limited to hematological malignancies but this modality is beginning to be explored clinically in the treatment of solid tumors⁹⁹. The limited success of CAR T cell therapy against solid tumors may be due to many factors, such as (i) The lack of a unique tumor-associated antigen (TAA) in most cancers, (ii) The inability of *ex vivo* expanded CAR T cells to persist and proliferate following adoptive transfer, (iii) The lack of survival and growth factors (e.g., IL-2), (iv) The presence of immunosuppressive molecules and cells and (v) The metabolically hostile tumor microenvironment¹⁰⁰ (Table1).

New targets for solid tumors that are beginning to enter clinical studies include mesothelin for the treatment of mesothelioma¹¹⁹⁻¹²¹ pancreatic^{121,122} and ovarian cancer,¹¹⁶ disialoganglioside GD2^{123,124} and EGFRVIII¹²⁵ for CNS malignancies and mucin-16^{126,127} to treat ovarian cancer. The ACT is a promising treatment modality which can eradicate primary and metastatic tumor cells and people are increasingly learning how to direct it against diverse cancers^{128,129}. Better understanding the importance of CAR-T-cell therapy is a priority for future studies¹³⁰.

Immune checkpoint blockade: Checkpoint blockade, an approach to trigger antitumor immune responses, refers to the blockade of immune inhibitory pathways activated by tumoral cells¹³¹. In the 1990s, data from preclinical studies showed that blockade of immune checkpoints bolsters the T cell response and could result in tumor eradication¹³². Immunotherapies such as immune checkpoint blockers (ICBs) are an established therapeutic approach to cancer treatment. These agents are approved for the treatment of several malignancies such as melanoma, urothelial carcinoma, renal cell carcinoma and head and neck squamous cell carcinoma¹³³. ICBs act on cancer cells indirectly by removing the "brakes" that serve to regulate T lymphocytes, the main cells responsible for triggering an anticancer immune response¹³⁴⁻¹⁴². ICBs are an established class of immunotherapy that target negative regulators of T cell activation, specifically the immune checkpoints, cytotoxic T lymphocyte-associated antigen4 (CTLA4), programmed cell death1 (PD1) and programmed cell death ligand1 (PDL1). Inhibition of these immune checkpoint molecules prevents the down regulation of immune cells, leading to enhanced T cell activity, which ultimately results in increased antitumor immunity¹³⁴. The two immune checkpoint receptors, CTLA4 (also known as CD152) and PD1 (also known as CD279), which are both inhibitory receptors, regulate immune responses at different levels and by different mechanisms¹⁴³. CTLA4 provides inhibitory signals that may prevent adequate immune response to malignant cells. During early T cell activation CTLA4 is recruited to the plasma membrane, where it competes with the co-stimulatory receptor CD28 to bind to B7 ligands expressed on the antigen presenting cells (APCs)^{144,145}. CTLA4 is thought to bind with both higher avidity and affinity than CD28 to B7 ligands¹⁴⁶ (Fig. 3). CTLA4 suppresses T cell activation by competitively inhibiting CD28 binding to CD80 and/or CD86 and inducing downstream inhibitory signaling, which ultimately leads to decreased T cell proliferation and IL-2 secretion^{145,147}.

Ipilimumab (Yervoy), is an anti CTLA4 antibody, that was approved in 2011 by the FDA as a first-line therapy for metastatic melanoma based on clinical trials that showed prolongation of overall survival^{136,139,140}. Like CTLA4, PD1 is a transmembrane protein expressed in activated effector T cells but not in resting T cells¹⁴⁴. PD1 has two ligands, PDL1




Fig. 3: Interaction between T-cells and antigen presenting cells¹⁴⁸

and PDL2,^{149,150} which can be expressed on a variety of cells, including APCs, tumor cells and T cells themselves. When bound to its ligands, PD1 also inhibits signaling pathways that normally lead to an effective T cell response. In contrast to CTLA4, that seems to mainly function in early activation of T cells, the major role of PD1 is to limit the activity of T cells in peripheral tissues at the time of an inflammatory response to infection and to limit autoimmunity¹⁵¹⁻¹⁵⁷. Since 2010, additional immunotherapies have received FDA approval. ICBs including ipilimumab^{136,139}, nivolumab¹⁴⁰, pembrolizumab¹⁴¹, atezolizumab¹³⁸, avelumab¹³⁵ and durvalumab^{137,142} approved for a wide range of malignancies, including melanoma, non-small cell lung cancer (NSCLC), RCC, urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), Hodgkin lymphoma, Merkel cell carcinoma, microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancer, hepatocellular carcinoma and gastroesophageal junction adenocarcinoma. Although all ICBs benefits by enhancing immune system function, they can lead to adverse events (AEs) distinct from chemotherapy^{158,159} that include a range of gastrointestinal (GI), dermatologic, endocrine and hepatic toxicities as well as other less common inflammatory events¹⁶⁰. Immune checkpoint inhibition has already begun to change the

standards of care for patients¹⁶¹ and the future looks very bright for this important class of immunotherapy.

Combination therapy: Combination therapies development for cancer treatment has a long and distinguished history¹⁶²⁻¹⁶⁴. Monotherapy or single agent immunotherapy may be relatively ineffective in most of the patients with advanced cancers¹⁶⁵. It has been investigated that, in order to achieve complete remission, the combination of multiple therapeutics may be needed. Combination therapies are progressing rapidly that new combinations are being diagnosed almost monthly¹⁶⁶. Switching to combination therapy as a cancer treatment modality, which is nowadays utilized in adulthood cancer treatments as well as its previous application in childhood cancers, will further prevent mutational escape in malignant cells¹⁶⁷. Combination therapy is a treatment option when single agent therapy does not seem to be effective. Early results of combination trials suggest that the synergism of combined drugs evoke antitumor responses¹⁶⁸ and make more sustained and durable tumor destruction¹⁶⁹. Current efforts are focusing on new the potentials of combination strategies with synergistic antitumor activity, using immune checkpoint blockade as a partner of targeted agents¹⁶³. There are many challenges with the development of combination targeted

therapeutics for cancer. First is to assess the relation of the targeting agents and their presumed targets of interest, both in their appropriate disease context and in the wide range of their potential drug interactions with various downstream effectors¹⁷⁰. The rationale to combine different target therapies is really based on their mechanisms¹⁷¹. In the following part, there mentioned some combination therapies which have been gained till now.

A recent clinical trial on CTLA and anti PD1 combination therapy has demonstrated tumor regression in 50% of treated patients with advanced melanoma and in most of the cases with tumor regression of 80% or higher¹⁷². There are ongoing clinical trials with anti CTLA4 (ipilimumab, BMS or tremelimumab, MedImmune/AstraZeneca) plus anti PD1 or anti PDL1 in other cancer types, with preliminary data indicating promising results¹⁴⁰ that highlight this combination as an effective strategy. Also, Platinum-based doublet therapy (for example, cisplatin in combination with another cytotoxic agent) has been the standard therapy for patients with advanced-stage NSCLC¹⁷³. The combination of dabrafenib and trametinib was FDA approved in 2016 for treating BRAF-V600E-positive NSCLC¹⁷⁴ and also the combination of imatinib with a DC vaccine in a BCR-ABL lymphoma model resulted in decreased numbers of Treg cells, fewer metastases and increased T cell-derived IFN γ production compared with either monotherapy¹⁶⁹. Combination therapies are likely to be needed in the future that takes advantage of the new genomic technologies to understand the basis in individual tumors. Combination therapies are promising for the management of cancer because of their potential synergy which could lead to deeper responses but more work needs to be done to learn about tumor feedbacks and resistance mechanisms. Many combinational studies are allowed nowadays for the treatment of patients in the upfront setting due to poor overall results¹⁷⁵.

Biomarkers in cancer immunotherapy: Extraordinary advances in scientists' understanding of the cancer biology, underlies the progression and development of cancer as well as potential molecular targets for its treatment¹⁷⁶⁻¹⁷⁹. Biomarkers are defined by the World Health Organization (WHO) in 1993 as almost any measurement reflecting an interaction between a biological system and a potential hazard, which may be biological, chemical or physical^{180,181}. According to the FDA, a biomarker is a characteristic that can be evaluated as an indicator of a physiologic or a pathologic process or a pharmacological response to a therapeutic intervention¹⁸². Useful biomarkers can be grouped into six subtypes: Those for identifying risk factors, those for the early

diagnosis of diseases or abnormalities, those used to predict either prognosis or clinical responses to therapy, those that can identify the patients are most likely to benefit from a given treatment and those used as surrogate endpoints in clinical trials¹⁸³. Biomarkers can be measured alone or in a group, often called a biomarker panel, to infer risk, diagnosis, prognosis and therapeutic response. DNA, RNA, proteins, metabolites, host cells and microorganisms can all function as biomarkers¹⁸⁴. The biomarker should be able to discriminate between pathologic and physiologic conditions, even if they are similar. Biomarkers should have defined molecular mechanisms of biological activities¹⁸⁵. Cancer biomarkers are typically evaluated in blood, body fluids or tumor specimens either ex vivo or in situ. To date, biomarkers of response have not served as primary end points for therapeutic trials that supported the approval of cancer therapies, although in selected cases they have been used as components of composite endpoints¹⁸⁰. They can also localize tumors and detect sites of different stages¹⁸¹. Biomarkers should be simple to measure, inexpensive and responsible for high throughput technologies to be used clinically¹⁸⁵⁻¹⁸⁷. Nowadays, the most frequently recommended biomarkers by clinical practice guidelines for epithelial ovarian cancer (EOC) (despite its low specificity), is Cancer antigen-125 (CA-125) (MUC 16)^{185,188}. Human epididymis protein 4 (HE4) has demonstrated good sensitivity and specificity in detecting EOC, overcoming the traditional role of CA-125¹⁸⁹. Both CA-125 and HE4 have been approved by the FDA for monitoring the treatment and disease recurrence¹⁹⁰. Alpha-fetoprotein (AFP), one of the first discovered protein tumor markers, is the main serological marker used in the diagnosis of hepatocellular carcinoma (HCC) since it is secreted by about half of HCC tumors¹⁹¹⁻¹⁹³. The most extensively validated and commonly used serum biomarker for detecting pancreatic cancer is carbohydrate antigen 19-9 (CA 19-9) which is a sialylated Lewis blood group antigen¹⁹⁴. It is also elevated in a variety of other malignancies such as hepatocellular carcinoma, cholangiocarcinoma and colorectal adenocarcinoma¹⁹⁵. The glycoprotein PSA is a well-recognized biomarker for detection of prostate cancer¹⁹⁶, which has changed the way of prostate cancer management after its FDA approval in 1984^{197,198}. Many studies have shown that miRNAs are a novel class of biomarkers for early detection of human cancers^{199,200}, due to their abundance and ease of detection in the bloodstream¹⁸⁵. CEA is also the most well-known and validated serum biomarker for epithelial malignancies²⁰¹. Molecular imaging technology provides a noninvasive mechanism to evaluate tumors and may be an ideal candidate for these purposes⁸. The promise of biomarker science and its successful application resides in the numerous

Table 2: List of biomarkers and surrogate end-points

Biomarkers	Related malignancy	References
CA-125 (MUC 16)	Epithelial ovarian cancer (EOC)	Strimbu and Tavel ¹⁸⁵ and Montagnana <i>et al.</i> ¹⁸⁸
HE4	Epithelial ovarian cancer (EOC)	Chen <i>et al.</i> ²⁰⁴
	AFP	hepatocellular carcinoma (HCC) Song <i>et al.</i> ¹⁹¹ , Goggins ¹⁹² , Ballehaninna and Chamberlain ¹⁹³ , Lukes <i>et al.</i> ¹⁹⁴ , Allhoff <i>et al.</i> ¹⁹⁵ , Cooner <i>et al.</i> ¹⁹⁶ , Motawi <i>et al.</i> ¹⁹⁷ , Bertoli <i>et al.</i> ¹⁹⁸ , Nakamura and Nishimura ¹⁹⁹ , Kelloff and Sigman ²⁰⁰ , Das <i>et al.</i> ²⁰¹ , Anastasi <i>et al.</i> ²⁰² and Hanash <i>et al.</i> ²⁰³
CA 19-9	Pancreatic cancer	Lukes <i>et al.</i> ¹⁹⁴ and Allhoff <i>et al.</i> ¹⁹⁵
	Hepatocellular carcinoma	
	Cholangiocarcinoma	
	Colorectal adenocarcinoma	
PSA	Prostate cancer	Nakamura and Nishimura ¹⁹⁹ and Kelloff. and Sigman ²⁰⁰
miRNAs	human cancers	Patz <i>et al.</i> ²⁰⁵ and Finn ²⁴
CEA	Epithelial malignancies	Das <i>et al.</i> ²⁰¹
CEA, RBP, SCC and α -1 antitrypsin	Lung cancer patients	Patz <i>et al.</i> ²⁰⁵ and Mellman <i>et al.</i> ²⁰⁶

scientific disciplines and cancer research projects²⁰². Biomarkers have significant potential for preventing and diagnosis the human cancers in different stages²⁰³. Promising and emerging biomarkers should routinely be implemented as exploratory end-points into ongoing clinical trials, in order to permit full validation and broader application¹⁸⁰ (Table 2).

CONCLUSION

Immuno oncology is an exciting field of cancer treatment with the potential to impact the management of numerous malignancies. Cancer immunotherapy restrains the patient's immune system to fight against cancer and is emerging as a significant modality in combination with conventional therapies recent results have allowed cancer immunotherapy to finally come of age, therefore it merits serious consideration of the clinical oncology communities. In the last 25 years, remarkable progress has been made in the field of cancer immunotherapy. In particular, several immunotherapy drugs have been approved for the treatment of several types of cancer with impressive and durable clinical responses. The present review has illustrated some of the mechanisms and latest approaches to cancer immunotherapy. In summary, immune checkpoint inhibitors and antiangiogenic drugs are widely and increasingly prescribed and are under review for application in solid tumor management. The goal of cancer vaccines is to activate and expand cancer-specific T cells. This review had identified the top ranking immunotherapies that are the focus of ongoing validations and clinical translational works in specific types of cancer. It was also noted that combination strategies, due to their synergistic anti-cancer activity are promising for the treatment of advanced types of cancer. The ability of the immune system to specifically attack cancer cells coupled with its ability to adapt to an evolving tumor and its built-in function of memory, make it the most

powerful weapon for long-term control of cancer. Also anticipated that the development of predictive biomarkers as well as the competition among their manufacturer companies, will help to control the costs associated with these treatments in the future. Cancer immunotherapy seems to be competent in the treatment of advanced types of cancer and hence more effort is needed in order to develop this important field of science.

SIGNIFICANT STATEMENT

This study considered current strategies in a cancer vaccine, immune checkpoint blockade, oncolytic viruses and immune combination therapy. This study will help the researcher to uncover a critical area of cancer immunotherapy, Thus a new theory on the answer to the obstacle relates to the immunotherapy such as Car-T cell therapy, CTLA4 and PD-1 checkpoint blockade.

REFERENCES

- Dana, H., A. Mazraeh, G.M. Chalbatani, V. Marmari and H. Mahmoodzadeh *et al.*, 2017. Cloning and expression of C2 and V domains of ALCAM protein in *E. coli*/BL21 (DE3). *J. Clin. Microbiol.*, Vol. 6. 10.4172/2327-5073.1000271.
- Marmari, V., H. Mahmoodzadeh, H. Dana, G.M. Chalbatani and A. Mazraeh *et al.*, 2017. *In silico* analysis, cloning and expression of recombinant CD166 in *E. coli*/BL21 (DE3) as a marker for detection and treatment of colorectal cancer. *J. Med. Microb. Diagn.*, Vol. 6. 10.4172/2161-0703.1000249.
- Dana, H., G. Mahmoodi, V. Marmari, A. Mazraeh and M. Ebrahimi, 2016. An Overview of Cancer Stem Cell. *J. Stem Cell Res. Ther.*, 10.15406/jsrt.2016.01.00029
- Dana, H., V. Marmari, A. Mazraeh, A. Ghamari and M.M. Forghanifard, 2017. Cloning and expression of the V-domain of the CD166 in prokaryotic host cell. *Int. J. Cancer Ther. Oncol.*, Vol. 5, No. 1. 10.14319/ijcto.51.10.

5. Dana, H., V. Marmari, G. Mahmoodi, H. Mahmoodzadeh, M. Ebrahimi and N. Mehmandoost, 2016. CD166 as a stem cell marker? A potential target for therapy colorectal cancer? *J. Stem Cell Res. Ther.*, 1: 226-229.
6. Anand, P., A.B. Kunnumakara, C. Sundaram, K.B. Harikumar and S.T. Tharakan *et al.*, 2008. Cancer is a preventable disease that requires major lifestyle changes. *Pharmaceut. Res.*, 25: 2097-2116.
7. Ma, X. and H. Yu, 2006. Global burden of cancer. *Yale J. Biol. Med.*, 79: 85-94.
8. Juergens, R.A., K.A. Zukotynski, A. Singnurkar, D.P. Snider, J.F. Valliant and K.Y. Gulenchyn, 2016. Imaging biomarkers in immunotherapy: Supplementary issue: Biomarkers and their essential role in the development of personalised therapies (A). *Biomark. Cancer*, Vol. 8, No. 2. 10.4137/BIC.S31805.
9. Farkona, S., E.P. Diamandis and I.M. Blasutig, 2016. Cancer immunotherapy: The beginning of the end of cancer? *BMC Med.*, Vol. 14, No. 1. 10.1186/s12916-016-0623-5.
10. Huang, Y., B.Y. Kim, C.K. Chan, S.M. Hahn, I.L. Weissman and W. Jiang, 2018. Improving immune-vascular crosstalk for cancer immunotherapy. *Nat. Rev. Immunol.*, 18: 195-203.
11. Sharma, P., K. Wagner, J.D. Wolchok and J.P. Allison, 2011. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. *Nat. Rev. Cancer*, 11: 805-812.
12. Waldmann, T.A., 2003. Immunotherapy: Past, present and future. *Nat. Med.*, 9: 269-277.
13. Syn, N.L., M.W. Teng, T.S. Mok and R.A. Soo, 2017. De-novo and acquired resistance to immune checkpoint targeting. *Lancet Oncol.*, 18: e731-e741.
14. Blattman, J.N. and P.D. Greenberg, 2004. Cancer immunotherapy: A treatment for the masses. *Science*, 305: 200-205.
15. Marin-Acevedo, J.A., B. Dholaria, A.E. Soyano, K.L. Knutson, S. Chumsri and Y. Lou, 2018. Next generation of immune checkpoint therapy in cancer: New developments and challenges. *J. Hematol. Oncol.*, Vol. 11, No. 1. 10.1186/s13045-018-0582-8.
16. Schreiber, R.D., L.J. Old and M.J. Smyth, 2011. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. *Science*, 331: 1565-1570.
17. Hunter, P., 2014. Vaccines against cancer: Despite setbacks, attempts to harness the patient's immune system to fight tumor cells show promise in clinical trials. *EMBO Rep.*, 15: 485-488.
18. Moreau, P., M.V. Mateos, J. Blade, L. Benboubker and J. de la Rubia *et al.*, 2014. An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma. *Blood*, 124: 176-176.
19. Wang, R.F. and H.Y. Wang, 2017. Immune targets and neoantigens for cancer immunotherapy and precision medicine. *Cell Res.*, 27: 11-37.
20. Schumacher, T.N. and R.D. Schreiber, 2015. Neoantigens in cancer immunotherapy. *Science*, 348: 69-74.
21. Efremova, M., F. Finotello, D. Rieder and Z. Trajanoski, 2017. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. *Front. Immunol.*, Vol. 8. 10.3389/fimmu.2017.01679.
22. Fritsch, E.F., N. Hacohen and C.J. Wu, 2014. Personal neoantigen cancer vaccines: The momentum builds. *Oncoimmunology*, Vol. 3, No. 6. 10.4161/onci.29311.
23. Hacohen, N., E.F. Fritsch, T.A. Carter, E.S. Lander and C.J. Wu, 2013. Getting personal with neoantigen-based therapeutic cancer vaccines. *Cancer Immunol. Res.*, 1: 11-15.
24. Finn, O.J., 2018. The dawn of vaccines for cancer prevention. *Nat. Rev. Immunol.*, 18: 183-194.
25. Coulie, P.G., B.J. van den Eynde, P. van der Bruggen and T. Boon, 2014. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. *Nat. Rev. Cancer*, 14: 135-146.
26. Currie, G.A., 1972. Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer. *Br. J. Cancer*, 26: 141-153.
27. Mahdavi, M., V. Moreau and M. Kheirollahi, 2017. Identification of B and T cell epitope based peptide vaccine from IGF-1 receptor in breast cancer. *J. Mol. Graphics Modell.*, 75: 316-321.
28. Zahm, C.D., V. Colluru and D.G. McNeel, 2017. Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8⁺ T cells. *Cancer Immunol. Res.*, 5: 630-641.
29. Song, Q., C.D. Zhang and X.H. Wu, 2018. Therapeutic cancer vaccines: From initial findings to prospects. *Immunol. Lett.*, 196: 11-21.
30. Melief, C.J., T. van Hall, R. Arens, F. Ossendorp and S.H. van der Burg, 2015. Therapeutic cancer vaccines. *J. Clin. Investig.*, 125: 3401-3412.
31. Roden, R. and T.C. Wu, 2006. How will HPV vaccines affect cervical cancer? *Nat. Rev. Cancer*, 6: 753-763.
32. Schiller, J.T., X. Castellsague and S.M. Garland, 2012. A review of clinical trials of human papillomavirus prophylactic vaccines. *Vaccine*, 30: F123-F138.
33. Markowitz, L.E., G. Liu, S. Hariri, M. Steinau, E.F. Dunne and E.R. Unger, 2016. Prevalence of HPV after introduction of the vaccination program in the United States. *Pediatrics*, Vol. 137, No. 3. 10.1542/peds.2015-1968.
34. Harper, D.M. and L.R. DeMars, 2017. HPV vaccines-A review of the first decade. *Gynecol. Oncol.*, 146: 196-204.

35. Filley, A.C. and M. Dey, 2017. Dendritic cell based vaccination strategy: An evolving paradigm. *J. Neuro-Oncol.*, 133: 223-235.
36. Small, E.J., L. Raymond, T.A. Gardner, L.I. Karsh and L. Fong *et al.*, 2015. A randomized phase II trial of sipuleucel-T with concurrent vs sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. *Clin. Cancer Res.* 10.1158/1078-0432.CCR-15-0079.
37. Lilleby, W., G. Gaudernack, P.F. Brunsvig, L. Vlatkovic and M. Schulz *et al.*, 2017. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. *Cancer Immunol. Immunother.*, 66: 891-901.
38. Obara, W., M. Eto, H. Mimata, K. Kohri and N. Mitsuhashi *et al.*, 2016. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. *Ann. Oncol.*, 28: 798-803.
39. Yamasaki, S., Y. Miura, J. Davydova, S.M. Vickers and M. Yamamoto, 2013. Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer. *Int. J. Cancer*, 133: 88-97.
40. Inoges, S., S. Tejada, A.L.D. Cerio, J.G. Perez-Larraya and J. Espinos *et al.*, 2017. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. *J. Transl. Med.*, Vol. 15, No. 1. 10.1186/s12967-017-1202-z.
41. Pardi, N., M.J. Hogan, F.W. Porter and D. Weissman, 2018. mRNA vaccines—a new era in vaccinology. *Nat. Rev. Drug Discov.*, 17: 261-279.
42. Santos, P.M. and L.H. Butterfield, 2018. Dendritic cell-based cancer vaccines. *J. Immunol.*, 200: 443-449.
43. Benteyn, D., C. Heirman, A. Bonehill, K. Thielemans and K. Breckpot, 2015. mRNA-based dendritic cell vaccines. *Expert Rev. Vaccines*, 14: 161-176.
44. Mitchell, D.A., K.A. Batich, M.D. Gunn, M.N. Huang and L. Sanchez-Perez *et al.*, 2015. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. *Nature*, 519: 366-369.
45. Van Lint, S., D. Renmans, K. Broos, H. Dewitte and I. Lentacker *et al.*, 2015. The ReNAissanCe of mRNA-based cancer therapy. *Expert Rev. Vaccines*, 14: 235-251.
46. Batich, K.A., E.A. Reap, G.E. Archer, L. Sanchez-Perez and S.K. Nair *et al.*, 2017. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. *Clin. Cancer Res.*, 23: 1898-1909.
47. Guevera-Patino, J.A., M.J. Turk, J.D. Wolchok and A.N. Houghton, 2003. Immunity to cancer through immune recognition of altered self: Studies with melanoma. *Adv. Cancer Res.*, 90: 158-179.
48. Banchemereau, J. and K. Palucka, 2018. Immunotherapy: Cancer vaccines on the move. *Nat. Rev. Clin. Oncol.*, 15: 9-10.
49. Howells, A., G. Marelli, N.R. Lemoine and Y. Wang, 2017. Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer. *Front. Oncol.*, Vol. 7. 10.3389/fonc.2017.00195.
50. Kelly, E. and S.J. Russell, 2007. History of oncolytic viruses: Genesis to genetic engineering. *Mol. Ther.*, 15: 651-659.
51. Dock, G., 1904. The influence of complicating diseases upon leukaemia. *Am. J. Med. Sci.*, 127: 563-592.
52. Bluming, A. and J. Ziegler, 1971. Regression of Burkitt's lymphoma in association with measles infection. *Lancet*, 298: 105-106.
53. Taqi, A.M., M.B. Abdurrahman, A.M. Yakubu and A.F. Fleming, 1981. Regression of Hodgkin's disease after measles. *Lancet*, 317: 1112-1112.
54. Delwar, Z., K. Zhang, P.S. Rennie and W. Jia, 2016. Oncolytic virotherapy for urological cancers. *Nat. Rev. Urol.*, 13: 334-352.
55. Gujar, S., J.G. Pol, Y. Kim, P.W. Lee and G. Kroemer, 2017. Antitumor benefits of antiviral immunity: An underappreciated aspect of oncolytic virotherapies. *Trends Immunol.*, 39: 209-221.
56. Lichty, B.D., C.J. Breitbach, D.F. Stojdl and J.C. Bell, 2014. Going viral with cancer immunotherapy. *Nat. Rev. Cancer*, 14: 559-567.
57. Maia, M.C. and A.R. Hansen, 2017. A comprehensive review of immunotherapies in prostate cancer. *Crit. Rev. Oncol. Hematol.*, 113: 292-303.
58. Taguchi, S., H. Fukuhara, Y. Homma and T. Todo, 2017. Current status of clinical trials assessing oncolytic virus therapy for urological cancers. *Int. J. Urol.*, 24: 342-351.
59. Pease, D.F. and R.A. Kratzke, 2017. Oncolytic viral therapy for mesothelioma. *Front. Oncol.*, Vol. 7. 10.3389/fonc.2017.00179.
60. Thorne, S.H., T. Hermiston and D. Kirn, 2005. Oncolytic virotherapy: Approaches to tumor targeting and enhancing antitumor effects. *Seminars Oncol.*, 32: 537-548.
61. Bell, J. and G. McFadden, 2014. Viruses for tumor therapy. *Cell Host Microbe*, 15: 260-265.
62. Marcato, P., M. Shmulevitz, D. Pan, D. Stoltz and P.W.K. Lee, 2007. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity and apoptosis-dependent release. *Mol. Ther.*, 15: 1522-1530.
63. Meyers, D.E., S. Thakur, C.M. Thirukkumaran and D.G. Morris, 2017. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. *Blood Cancer J.*, Vol. 7, No. 12. 10.1038/s41408-017-0020-0.
64. Russell, S.J. and K.W. Peng, 2017. Oncolytic virotherapy: A contest between apples and oranges. *Mol. Ther.*, 25: 1107-1116.
65. Wennier, S.T., J. Liu and G. McFadden, 2012. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. *Curr. Pharm. Biotechnol.*, 13: 1817-1833.

66. Kroemer, G., L. Galluzzi, O. Kepp and L. Zitvogel, 2013. Immunogenic cell death in cancer therapy. *Annu. Rev. Immunol.*, 31: 51-72.
67. Kaufman, H.L., F.J. Kohlhapp and A. Zloza, 2015. Oncolytic viruses: A new class of immunotherapy drugs. *Nat. Rev. Drug Discov.*, 14: 642-662.
68. Breitbach, C.J., K. Parato, J. Burke, T.H. Hwang, J.C. Bell and D.H. Kirn, 2015. Pexa-Vec double agent engineered vaccinia: Oncolytic and active immunotherapeutic. *Curr. Opin. Virol.*, 13: 49-54.
69. Tong, A.W., N. Senzer, V. Cerullo, N.S. Templeton, A. Hemminki and J. Nemunaitis, 2012. Oncolytic viruses for induction of anti-tumor immunity. *Curr. Pharm. Biotechnol.*, 13: 1750-1760.
70. Fukuhara, H., Y. Ino and T. Todo, 2016. Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Sci.*, 107: 1373-1379.
71. Maroun, J., M. Munoz-Alia, A. Ammayappan, A. Schulze, K.W. Peng and S. Russell, 2017. Designing and building oncolytic viruses. *Future Virol.*, 12: 193-213.
72. Fountzilias, C., S. Patel and D. Mahalingam, 2017. Oncolytic virotherapy, updates and future directions. *Oncotarget*, 8: 102617-102639.
73. Liu, T.C., E. Galanis and D. Kirn, 2007. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. *Nat. Rev. Clin. Oncol.*, 4: 101-117.
74. Gromeier, M., S. Lachmann, M.R. Rosenfeld, P.H. Gutin and E. Wimmer, 2000. Intergeneric poliovirus recombinants for the treatment of malignant glioma. *Proc. Natl. Acad. Sci. USA.*, 97: 6803-6808.
75. Ochiai, H., S.A. Campbell, G.E. Archer, T.A. Chewning and E. Dragunsky *et al.*, 2006. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. *Clin. Cancer Res.*, 12: 1349-1354.
76. Reddy, P.S., K.D. Burroughs, L.M. Hales, S. Ganesh and B.H. Jones *et al.*, 2007. Seneca Valley virus, a systemically deliverable oncolytic picornavirus and the treatment of neuroendocrine cancers. *J. Natl. Cancer Inst.*, 99: 1623-1633.
77. Prestwich, R.J., F. Errington, E.J. Ilett, R.S. Morgan and K.J. Scott *et al.*, 2008. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. *Clin. Cancer Res.*, 14: 7358-7366.
78. Toda, M., S.D. Rabkin, H. Kojima and R.L. Martuza, 1999. Herpes simplex virus as an *in situ* cancer vaccine for the induction of specific anti-tumor immunity. *Hum. Gene Ther.*, 10: 385-393.
79. Toda, M., R.L. Martuza, H. Kojima and S.D. Rabkin, 1998. *In situ* cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. *J. Immunol.*, 160: 4457-4464.
80. Thorne, S.H. and C.H. Contag, 2008. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. *Gene Ther.*, 15: 753-758.
81. Lee, P. and S. Gujar, 2018. Potentiating prostate cancer immunotherapy with oncolytic viruses. *Nat. Rev. Urol.*, 15: 235-250.
82. Tanoue, K., A.R. Shaw, N. Watanabe, C.E. Porter and B. Rana *et al.*, 2017. Armed oncolytic adenovirus expressing PD-L1 mini-body enhances anti-tumor effects of chimeric antigen receptor T-cells in solid tumors. *Cancer Res.*, 77: 2040-2051.
83. Ma, G., H. Shimada, K. Hiroshima, Y. Tada, N. Suzuki and M. Tagawa, 2008. Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China. *Drug Design Dev. Ther.*, 2: 115-122.
84. Andtbacka, R.H., H.L. Kaufman, F. Collichio, T. Amatruda and N. Senzer *et al.*, 2015. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. *J. Clin. Oncol.*, 33: 2780-2788.
85. Babiker, H.M., I.B. Riaz, M. Husnain and M.J. Borad, 2017. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. *Oncol. Virother.*, 6: 11-18.
86. US Food and Drug Administration, 2015. FDA approves first-of-its-kind product for the treatment of melanoma. Silver Spring MD, 2015: 611-619.
87. Rehman, H., A.W. Silk, M.P. Kane and H.L. Kaufman, 2016. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. *J. Immunother. Cancer*, Vol. 4, No. 1. 10.1186/s40425-016-0158-5.
88. Schwartsman, G., K. Perez, J.E. Flynn, J.N. Myers and H. Tawbi, 2017. Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. *J. Immunother. Cancer*, Vol. 5, No. 1. 10.1186/s40425-017-0250-5.
89. Puzanov, I., M.M. Milhem, D. Minor, O. Hamid and A. Li *et al.*, 2016. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. *J. Clin. Oncol.*, 34: 2619-2626.
90. Hu, J.C., R.S. Coffin, C.J. Davis, N.J. Graham and N. Groves *et al.*, 2006. A phase I study of Onco VEX^{GM-CSF}, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. *Clin. Cancer Res.*, 12: 6737-6747.
91. Tomazin, R., N.E. van Schoot, K. Goldsmith, P. Jugovic, P. Sempe, K. Fruh and D.C. Johnson, 1998. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. *J. Virol.*, 72: 2560-2563.
92. Qureshi, O.S., Y. Zheng, K. Nakamura, K. Attridge and C. Manzotti *et al.*, 2011. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. *Science*, 332: 600-603.

93. Miest, T.S. and R. Cattaneo, 2014. New viruses for cancer therapy: Meeting clinical needs. *Nat. Rev. Microbiol.*, 12: 23-34.
94. DeVita, Jr.V.T. and S.A. Rosenberg, 2012. Two hundred years of cancer research. *N. Engl. J. Med.*, 366: 2207-2214.
95. Klein, G., H.O. Sjogren, E. Klein and K.E. Hellstrom, 1960. Demonstration of resistance against methylcholanthreneinduced sarcomas in the primary autochthonous host. *Cancer Res.*, 20: 1561-1572.
96. Mitchison, N.A., 1955. Studies on the immunological response to foreign tumor transplants in the mouse: I. The role of lymph node cells in conferring immunity by adoptive transfer. *J. Exp. Med.*, 102: 157-177.
97. Khalil, D.N., E.L. Smith, R.J. Brentjens and J.D. Wolchok, 2016. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. *Nat. Rev. Clin. Oncol.*, 13: 273-290.
98. Mirzaei, H.R., A. Rodriguez, J. Shepphird, C.E. Brown and B. Badie, 2017. Chimeric antigen receptors T cell therapy in solid tumor: Challenges and clinical applications. *Front. Immunol.*, Vol. 8. 10.3389/fimmu.2017.01850.
99. Altschmidt, U., E. Klundt and B. Groner, 1997. Adoptive transfer of *in vitro*-targeted, activated T lymphocytes results in total tumor regression. *J. Immunol.*, 159: 5509-5515.
100. Brentjens, R.J., I. Riviere, J.H. Park, M.L. Davila and X. Wang *et al.*, 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood*, 118: 4817-4828.
101. Kalos, M., B.L. Levine, D.L. Porter, S. Katz, S.A. Grupp, A. Bagg and C.H. June, 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci. Transl. Med.*, Vol. 3. 10.1126/scitranslmed.3002842.
102. Restifo, N.P., M.E. Dudley and S.A. Rosenberg, 2012. Adoptive immunotherapy for cancer: Harnessing the T cell response. *Nat. Rev. Immunol.*, 12: 269-281.
103. Robbins, P.F., R.A. Morgan, S.A. Feldman, J.C. Yang and R.M. Sherry *et al.*, 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *J. Clin. Oncol.*, 29: 917-924.
104. Kochenderfer, J.N., M.E. Dudley, S.A. Feldman, W.H. Wilson and D.E. Spaner *et al.*, 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood*, 119: 2709-2720.
105. Sengupta, S., G. Mao, Z. Gokaslan and P. Sampath, 2017. Chimeric antigen receptors for treatment of glioblastoma: A practical review of challenges and ways to overcome them. *Cancer Gene Ther.*, 24: 121-129.
106. Brudno, J.N. and J.N. Kochenderfer, 2016. Toxicities of chimeric antigen receptor T cells: Recognition and management. *Blood*, 127: 3321-3330.
107. Lee, D.W., R. Gardner, D.L. Porter, C.U. Louis and N. Ahmed *et al.*, 2014. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*, 124: 188-195.
108. Maude, S.L., D. Barrett, D.T. Teachey and S.A. Grupp, 2014. Managing cytokine release syndrome associated with novel T cell-engaging therapies. *Cancer J.*, 20: 119-122.
109. Hu, Y., J. Sun, Z. Wu, J. Yu and Q. Cui *et al.*, 2016. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. *J. Hematol. Oncol.*, Vol. 9. 10.1186/s13045-016-0299-5.
110. Batlevi, C.L., E. Matsuki, R.J. Brentjens and A. Younes, 2016. Novel immunotherapies in lymphoid malignancies. *Nat. Rev. Clin. Oncol.*, 13: 25-40.
111. Engel, P., L.J. Zhou, D.C. Ord, S. Sato, B. Koller and T.F. Tedder, 1995. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. *Immunity*, 3: 39-50.
112. Rickert, R.C., K. Rajewsky and J. Roes, 1995. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. *Nature*, 376: 352-355.
113. Brentjens, R.J., J.B. Latouche, E. Santos, F. Marti and M.C. Gong *et al.*, 2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. *Nat. Med.*, 9: 279-286.
114. Li, Y.S., K. Hayakawa and R.R. Hardy, 1993. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. *J. Exp. Med.*, 178: 951-960.
115. Li, Y.S., R. Wasserman, K. Hayakawa and R.R. Hardy, 1996. Identification of the earliest B lineage stage in mouse bone marrow. *Immunity*, 5: 527-535.
116. John, L.B., C. Devaud, C.P.M. Duong, C. Yong and P.A. Beavis *et al.*, 2013. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. *Clin. Cancer Res.*, 19: 5636-5646.
117. Adusumilli, P.S., L. Cherkassky, J. Villena-Vargas, C. Colovos and E. Servais *et al.*, 2014. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. *Sci. Transl. Med.*, Vol. 6. 10.1126/scitranslmed.3010162.
118. Beatty, G.L., A.R. Haas, M.V. Maus, D.A. Torigian and M.C. Soulen *et al.*, 2014. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. *Cancer Immunol. Res.*, 2: 112-120.

119. Tanyi, J.L., A.R. Haas, G.L. Beatty, M.A. Morgan and C.J. Stashwick *et al.*, 2015. Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers. *Cancer Res.*, Vol. 75. 10.1158/1538-7445.AM2015-CT105.
120. Beatty, G.L., M.H. O'Hara, A.M. Nelson, M. McGarvey and D.A. Torigian *et al.*, 2015. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. *J. Clin. Oncol.*, 33: 3007-3007.
121. Louis, C.U., B. Savoldo, G. Dotti, M. Pule and E. Yvon *et al.*, 2011. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood*, 118: 6050-6056.
122. Singh, N., X. Liu, J. Hulitt, S. Jiang and C.H. June *et al.*, 2014. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. *Cancer Immunol. Res.*, 2: 1059-1070.
123. Johnson, L.A., J. Scholler, T. Ohkuri, A. Kosaka and P.R. Patel *et al.*, 2015. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. *Sci. Transl. Med.*, Vol. 7. 10.1126/scitranslmed.aaa4963.
124. Koneru, M., T.J. Purdon, D. Spriggs, S. Koneru and R.J. Brentjens, 2015. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors *in vivo*. *Oncoimmunology*, Vol. 4. 10.4161/2162402X.2014.994446.
125. Koneru, M., R. O'Cearbhaill, S. Pendharkar, D.R. Spriggs and R.J. Brentjens, 2015. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer. *J. Transl. Med.*, Vol. 13. 10.1186/s12967-015-0460-x.
126. Shi, H., X. Qi, B. Ma, Y. Cao, L. Wang, L. Sun and H. Niu, 2015. The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies. *Chin. J. Cancer Res.*, 27: 128-137.
127. Hinrichs, C.S. and N.P. Restifo, 2013. Reassessing target antigens for adoptive T-cell therapy. *Nat. Biotechnol.*, 31: 999-1008.
128. Brudno, J.N. and J.N. Kochenderfer, 2018. Chimeric antigen receptor T-cell therapies for lymphoma. *Nat. Rev. Clin. Oncol.*, 15: 31-46.
129. Pardoll, D.M. and S.L. Topalian, 1998. The role of CD4⁺ T cell responses in antitumor immunity. *Curr. Opin. Immunol.*, 10: 588-594.
130. Leach, D.R., M.F. Krummel and J.P. Allison, 1996. Enhancement of antitumor immunity by CTLA-4 blockade. *Science*, 271: 1734-1736.
131. Clarke, J.M., D.J. George, S. Lisi and A.K.S. Salama, 2018. Immune checkpoint blockade: The new frontier in cancer treatment. *Targeted Oncol.*, 13: 1-20.
132. Buchbinder, E.I. and A. Desai, 2016. CTLA-4 and PD-1 pathways: Similarities, differences and implications of their inhibition. *Am. J. Clin. Oncol.*, 39: 98-106.
133. Fujii, R., E.R. Friedman, J. Richards, K.Y. Tsang, C.R. Heery, J. Schlom and J.W. Hodge, 2016. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. *Oncotarget*, 7: 33498-33511.
134. Hodi, F.S., S.J. O'Day, D.F. McDermott, R.W. Weber and J.A. Sosman *et al.*, 2010. Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.*, 363: 711-723.
135. Nalley, C., 2018. Durvalumab approval expanded to reduce the risk of non-small cell lung cancer progressing. *Oncology Times*. <https://journals.lww.com/oncology-times/blog/fdaactionsandupdates/Pages/post.aspx?PostID=287>
136. Ning, Y.M., D. Suzman, V.E. Maher, L. Zhang and S. Tang *et al.*, 2017. FDA approval summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum containing chemotherapy. *Oncologist*, 22: 743-749.
137. Robert, C., L. Thomas, I. Bondarenko, S. O'Day and J. Weber *et al.*, 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N. Engl. J. Med.*, 364: 2517-2526.
138. Sharma, P. and J.P. Allison, 2015. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. *Cell*, 161: 205-214.
139. Sul, J., G.M. Blumenthal, X. Jiang, K. He, P. Keegan and R. Pazdur, 2016. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. *Oncologist*, 21: 643-650.
140. Syed, Y.Y., 2017. Durvalumab: First global approval. *Drugs*, 77: 1369-1376.
141. Pardoll, D.M., 2012. The blockade of immune checkpoints in cancer immunotherapy. *Nat. Rev. Cancer*, 12: 252-264.
142. Schwartz, R.H., 1992. Costimulation of T lymphocytes: The role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. *Cell*, 71: 1065-1068.
143. Krummel, M.F. and J.P. Allison, 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *J. Exp. Med.*, 182: 459-465.
144. Linsley, P.S., W. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle and J.A. Ledbetter, 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. *J. Exp. Med.*, 174: 561-569.

145. Krummel, M.F. and J.P. Allison, 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. *J. Exp. Med.*, 183: 2533-2540.
146. Wykes, M.N. and S.R. Lewin, 2018. Immune checkpoint blockade in infectious diseases. *Nat. Rev. Immunol.*, 18: 91-104.
147. Keir, M.E., M.J. Butte, G.J. Freeman and A.H. Sharpe, 2008. PD-1 and its ligands in tolerance and immunity. *Annu. Rev. Immunol.*, 26: 677-704.
148. Dong, H., G. Zhu, K. Tamada and L. Chen, 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat. Med.*, 5: 1365-1369.
149. Freeman, G.J., A.J. Long, Y. Iwai, K. Bourque and T. Chernova *et al.*, 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J. Exp. Med.*, 192: 1027-1034.
150. Ishida, Y., Y. Agata, K. Shibahara and T. Honjo, 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J.*, 11: 3887-3895.
151. Latchman, Y., C.R. Wood, T. Chernova, D. Chaudhary and M. Borde *et al.*, 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat. Immunol.*, 2: 261-268.
152. Keir, M.E., S.C. Liang, I. Guleria, Y.E. Latchman and A. Qipo *et al.*, 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. *J. Exp. Med.*, 203: 883-895.
153. Nishimura, H., M. Nose, H. Hiai, N. Minato and T. Honjo, 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity*, 11: 141-151.
154. Nishimura, H., T. Okazaki, Y. Tanaka, K. Nakatani and M. Hara *et al.*, 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. *Science*, 291: 319-322.
155. Okazaki, T. and T. Honjo, 2007. PD-1 and PD-1 ligands: From discovery to clinical application. *Int. Immunol.*, 19: 813-824.
156. Weber, J.S., M. Postow, C.D. Lao and D. Schadendorf, 2016. Management of adverse events following treatment with anti-programmed death-1 agents. *Oncologist*, 21: 1230-1240.
157. Weber, J.S., K.C. Kahler and A. Hauschild, 2012. Management of immune-related adverse events and kinetics of response with ipilimumab. *J. Clin. Oncol.*, 30: 2691-2697.
158. Michot, J.M., C. Bigenwald, S. Champiat, M. Collins and F. Carbonnel *et al.*, 2016. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. *Eur. J. Cancer*, 54: 139-148.
159. Goodman, A., S.P. Patel and R. Kurzrock, 2017. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. *Nat. Rev. Clin. Oncol.*, 14: 203-220.
160. DeVita, V.T. and P.S. Schein, 1973. The use of drugs in combination for the treatment of cancer: Rationale and results. *N. Engl. J. Med.*, 288: 998-1006.
161. DeVita, V.T.Jr., R.C. Young and G.P. Canellos, 1975. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. *Cancer*, 35: 98-110.
162. Frei, E., 1972. Combination cancer therapy: Presidential address. *Cancer Res.*, 32: 2593-2607.
163. Mahoney, K.M., P.D. Rennert and G.J. Freeman, 2015. Combination cancer immunotherapy and new immunomodulatory targets. *Nat. Rev. Drug Discov.*, 14: 561-584.
164. Melero, I., D.M. Berman, M.A. Aznar, A.J. Korman, J.L.P. Gracia and J. Haanen, 2015. Evolving synergistic combinations of targeted immunotherapies to combat cancer. *Nat. Rev. Cancer*, 15: 457-472.
165. Westhoff, M.A., N. Marschall, M. Grunert, G. Karpel-Massler, S. Burdach and K.M. Debatin, 2018. Cell death-based treatment of childhood cancer. *Cell Death Dis.*, Vol. 9. 10.1038/ss41419-017-0062-z.
166. Moya-Horno, I., S. Viteri, N. Karachaliou and R. Rosell, 2018. Combination of immunotherapy with targeted therapies in advanced Non-Small Cell Lung Cancer (NSCLC). *Ther. Adv. Med. Oncol.*, Vol. 10. 10.1177/1758834017745012.
167. Vanneman, M. and G. Dranoff, 2012. Combining immunotherapy and targeted therapies in cancer treatment. *Nat. Rev. Cancer*, 12: 237-251.
168. Hait, W.N., 2009. Targeted cancer therapeutics. *Cancer Res.*, 69: 1263-1267.
169. Waeber, B., F. Feihl and L.M. Ruilope, 2009. Fixed-dose combinations as initial therapy for hypertension: A review of approved agents and a guide to patient selection. *Drugs*, 69: 1761-1776.
170. Wolchok, J.D., H. Kluger, M.K. Callahan, M.A. Postow and N.A. Rizvi *et al.*, 2013. Nivolumab plus ipilimumab in advanced melanoma. *N. Engl. J. Med.*, 369: 122-133.
171. Masters, G.A., D.H. Johnson and S. Temin, 2016. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. *J. Oncol. Pract.*, 12: 90-93.
172. Planchard, D., B. Besse, H.J. Groen, P.J. Souquet and E. Quoix *et al.*, 2016. Dabrafenib plus trametinib in patients with previously treated BRAF^{V600E}-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. *Lancet Oncol.*, 17: 984-993.
173. Ma, H., A. Davarifar and J.E. Amengual, 2018. The future of combination therapies for Peripheral T Cell Lymphoma (PTCL). *Curr. Hematol. Malignancy Rep.*, 13: 13-24.
174. Hanahan, D. and R.A. Weinberg, 2000. The hallmarks of cancer. *Cell*, 100: 57-70.

175. Hanahan, D. and R.A. Weinberg, 2011. Hallmarks of cancer: The next generation. *Cell*, 144: 646-674.
176. Luo, J., N.L. Solimini and S.J. Elledge, 2009. Principles of cancer therapy: Oncogene and non-oncogene addiction. *Cell*, 136: 823-837.
177. Polyak, K. and R.A. Weinberg, 2009. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat. Rev. Cancer*, 9: 265-273.
178. Neal, J.W., J.F. Gainor and A.T. Shaw, 2015. Developing biomarker-specific end points in lung cancer clinical trials. *Nat. Rev. Clin. Oncol.*, 12: 135-146.
179. Petrushenko, W., J.S. Gundara, P.R. de Reuver, G. O'Grady, J.S. Samra and A. Mittal, 2016. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. *Hepato Pancreato Biliary*, 18: 652-663.
180. Biomarkers Definitions Working Group, 2001. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. *Clin. Pharmacol. Ther.*, 69: 89-95.
181. Shariat, S.F., A. Semjonow, H. Lilja, C. Savage, A.J. Vickers and A. Bjartell, 2011. Tumor markers in prostate cancer I: Blood-based markers. *Acta Oncol.*, 50: 61-75.
182. Vargas, A.J. and C.C. Harris, 2016. Biomarker development in the precision medicine era: Lung cancer as a case study. *Nat. Rev. Cancer*, 16: 525-537.
183. Szajnik, M., M. Czystowska-Kuzmicz, E. Elishaev and T.L. Whiteside, 2016. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. *Expert Rev. Mol. Diagn.*, 16: 811-826.
184. Sidransky, D., 2002. Emerging molecular markers of cancer. *Nat. Rev. Cancer*, 2: 210-219.
185. Strimbu, K. and J.A. Tavel, 2010. What are biomarkers? *Curr. Opin. HIV AIDS*, 5: 463-466.
186. Scaletta, G., F. Plotti, D. Luvero, S. Capriglione and R. Montera *et al.*, 2017. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: A systematic review. *Expert Rev. Anticancer Ther.*, 17: 827-839.
187. Ferraro, S., F. Braga, M. Lanzoni, P. Boracchi, E.M. Biganzoli and M. Panteghini, 2013. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: A systematic review. *J. Clin. Pathol.*, 66: 273-281.
188. Montagnana, M., E. Danese, S. Giudici, M. Franchi, G.C. Guidi, M. Plebani and G. Lippi, 2011. HE4 in Ovarian Cancer: From Discovery to Clinical Application. In: *Advances in Clinical Chemistry*, Volume 55, Makowski, G.S. (Ed.). Academic Press, USA., ISBN: 9780123870438, pp: 1-20.
189. Llovet, J.M. and J. Bruix, 2003. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology*, 37: 429-442.
190. Sauzay, C., A. Petit, A.M. Bourgeois, J.C. Barbare, B. Chauffert, A. Galmiche and A. Houessinon, 2016. Alpha-fetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. *Clin. Chim. Acta*, 463: 39-44.
191. Song, P.P., J.F. Xia, Y. Inagaki, K. Hasegawa, Y. Sakamoto, N. Kokudo and W. Tang, 2016. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. *World J. Gastroenterol.*, 22: 262-274.
192. Goggins, M., 2005. Molecular markers of early pancreatic cancer. *J. Clin. Oncol.*, 23: 4524-4531.
193. Ballehaninna, U.K. and R.S. Chamberlain, 2012. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. *J. Gastrointest. Oncol.*, 3: 105-119.
194. Lukes, M., M. Urban, M. Zalesky, R. Zachoval, J. Heracek and E. Zdarsky, 2001. Prostate-specific antigen: Current status. *Folia Biol.*, 47: 41-49.
195. Allhoff, E., W. de Riese, M. Eifinger, J. Pethke and U. Jonas, 1989. Prostate-specific antigen-comparative clinical appreciation of a serodiagnostic measure after 8 years of experience. *World J. Urol.*, 7: 12-16.
196. Cooner, W.H., B.R. Mosley, C.L. Jr. Rutherford, J.H. Beard and H.S. Pond *et al.*, 1990. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. *J. Urol.*, 143: 1146-1152.
197. Motawi, T.K., S.M. Rizk, T.M. Ibrahim and I.A.R. Ibrahim, 2016. Circulating microRNAs, miR 92a, miR 100 and miR 143 as non invasive biomarkers for bladder cancer diagnosis. *Cell Biochem. Funct.*, 34: 142-148.
198. Bertoli, G., C. Cava and I. Castiglioni, 2015. MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. *Theranostics*, 5: 1122-1143.
199. Nakamura, H. and T. Nishimura, 2017. History, molecular features and clinical importance of conventional serum biomarkers in lung cancer. *Surg. Today*, 47: 1037-1059.
200. Kelloff, G.J. and C.C. Sigman, 2012. Cancer biomarkers: Selecting the right drug for the right patient. *Nat. Rev. Drug Discov.*, 11: 201-214.
201. Das, V., J. Kalita and M. Pal, 2017. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. *Biomed. Pharmacother.*, 87: 8-19.
202. Anastasi, E., G.G. Marchei, V. Viggiani, G. Gennarini, L. Frati and M.G. Reale, 2010. HE4: A new potential early biomarker for the recurrence of ovarian cancer. *Tumor Biol.*, 31: 113-119.

203. Hanash, S.M., C.S. Baik and O. Kallioniemi, 2011. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. *Nat. Rev. Clin. Oncol.*, 8: 142-150.
204. Chen, X., Y. Ba, L. Ma, X. Cai and Y. Yin *et al.*, 2008. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res.*, 18: 997-1006.
205. Patz, Jr.E.F., M.J. Campa, E.B. Gottlin, I. Kusmartseva, X.R. Guan and J.E. Herndon, 2007. Panel of serum biomarkers for the diagnosis of lung cancer. *J. Clin. Oncol.*, 25: 5578-5583.
206. Mellman, I., G. Coukos and G. Dranoff, 2011. Cancer immunotherapy comes of age. *Nature*, 480: 480-489.